ArticleTranslational lung cancer research2026
Exploring the effectiveness and sequence of brain local treatment combined with thoracic surgery in non-small cell lung cancer patients with brain oligometastasis.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) with brain metastases represents approximately 10% of new cancer cases globally. Brain local treatments in addition to resection of the primary lung tumor has been shown to benefit patients with oligometastases. This study aimed to identify the potential beneficiaries of brain local treatment and the timing of lung and brain treatment. Methods: A total of 198 patients diagnosed with NSCLC with synchronous limited brain metastases undergoing thoracic surgery were included. Kaplan-Meier analysis and Cox regression model were used to evaluate the associations between treatments patterns and prognosis. Results: Compared to patients who did not receive brain local treatment, significantly better prognosis was observed for those who received upfront brain treatment [overall survival (OS): hazard ratio (HR); 0.52, 95% confidence interval (CI): 0.28-0.97, P=0.04; progression-free survival (PFS): HR, 0.51; 95% CI: 0.32-0.84, P=0.007] and for those who received subsequent brain treatment (OS: HR, 0.50, 95% CI: 0.31-0.82, P=0.005; PFS: HR, 0.51; 95% CI: 0.35-0.74, P<0.001). Kaplan-Meier curves indicated that there was no significant difference in OS and PFS between the upfront and subsequent brain treatment groups. However, the postoperative brain recurrence rate in upfront group was significantly lower than that in subsequent group (24.0% Conclusions: We identified that local brain treatments combined with thoracic surgery serve as a significant protective factor for the prognosis of NSCLC patients with brain oligometastasis, particularly for those with solitary metastatic lesion. In comparison to subsequent brain treatment, upfront brain treatment was associated with a lower rate of postoperative brain recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.